AbbVie terminates collaboration with I-Mab for cancer drug development
AbbVie is terminating its agreement with I-Mab regarding the development and commercialization of certain CD47 antibodies and products. This decision comes after AbbVie had previously opted out of part of the pact last year. The termination of the agreement is based on program discontinuation and AbbVie's strategic decision.